{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:14:58Z","timestamp":1790363698036,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019324","name":"Virginia Marine Resources Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005911","name":"Najran University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.drudis.2025.104380","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T19:32:34Z","timestamp":1747337554000},"page":"104380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Advances in lipid-based nanoformulations for inhaled antibiotic therapy in respiratory infections"],"prefix":"10.1016","volume":"30","author":[{"given":"Mohammad H.","family":"Alyami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Zaki","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel A.","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyani","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104380_b0005","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.apsb.2021.05.015","article-title":"Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines","volume":"11","author":"Guo","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2025.104380_b0010","article-title":"Pulmonary inhalation for disease treatment: basic research and clinical translations","volume":"25","author":"Wang","year":"2024","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.drudis.2025.104380_b0015","first-page":"441308","article-title":"Inhaled antibiotics: dry or wet?","author":"Tiddens","year":"2014","journal-title":"Eur Resp J"},{"key":"10.1016\/j.drudis.2025.104380_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124182","article-title":"Pulmonary drug delivery devices and nanosystems as potential treatment strategies for acute respiratory distress syndrome (ARDS)","volume":"657","author":"Dhege","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0025","article-title":"Inhalation drug delivery in combating pulmonary infections: advances and challenges","volume":"89","author":"Kumbhar","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.drudis.2025.104380_b0030","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/tde-2017-0037","article-title":"Drug delivery to the lungs: challenges and opportunities","volume":"8","author":"Newman","year":"2017","journal-title":"Ther Deliv"},{"key":"10.1016\/j.drudis.2025.104380_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092179","article-title":"Lipid nanoparticles as delivery vehicles for inhaled therapeutics","volume":"10","author":"Leong","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2025.104380_b0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/jamp.2018.1508","article-title":"Devices for improved delivery of nebulized pharmaceutical aerosols to the lungs","volume":"32","author":"Longest","year":"2019","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.drudis.2025.104380_b0045","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/ac0c0c","article-title":"Inhalable liposomes for treating lung diseases: clinical development and challenges","volume":"16","author":"Ponkshe","year":"2021","journal-title":"Biomed Mater"},{"key":"10.1016\/j.drudis.2025.104380_b0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2019.05.043","article-title":"Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats","volume":"307","author":"Haque","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2025.104380_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118915","article-title":"Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections","volume":"575","author":"Yu","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124208","article-title":"Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. aeruginosa biofilm eradication","volume":"658","author":"Wang","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122667","article-title":"Microfluidics assembly of inhalable liposomal ciprofloxacin characterised by an innovative in vitro pulmonary model","volume":"635","author":"Zhang","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijpharm.2019.05.068","article-title":"Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation","volume":"566","author":"Khatib","year":"2019","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.drudis.2025.104380_b0075","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/10837450.2016.1228666","article-title":"Electrostatically entrapped colistin liposomes for the treatment of Pseudomonas aeruginosa infection","volume":"22","author":"Li","year":"2017","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.drudis.2025.104380_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123841","article-title":"Inhaled dry powder liposomal azithromycin for treatment of chronic lower respiratory tract infection","volume":"653","author":"Dallal Bashi","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fmicb.2017.00091","article-title":"Inhaled liposomal ciprofloxacin protects against a lethal infection in a murine model of pneumonic plague","volume":"8","author":"Hamblin","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2025.104380_b0090","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10517-020-04793-x","article-title":"Efficacy of inhalations of antituberculous compositions with different length of experimental therapy course in mice","volume":"168","author":"Shkurupy","year":"2020","journal-title":"Bull Exp Biol Med"},{"key":"10.1016\/j.drudis.2025.104380_b0095","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1021\/acsinfecdis.4c00192","article-title":"Intranasal administration of bedaquiline-loaded fucosylated liposomes provides anti-tubercular activity while reducing the potential for systemic side effects","volume":"10","author":"Marwitz","year":"2024","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.drudis.2025.104380_b0100","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/03639045.2022.2135101","article-title":"A facile one-step jet-milling approach for the preparation of proliposomal dry powder for inhalation as effective delivery system for anti-TB therapeutics","volume":"48","author":"Srichana","year":"2022","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124608","article-title":"Development of a proliposomal pretomanid dry powder inhaler as a novel alternative approach for combating pulmonary tuberculosis","volume":"664","author":"Aekwattanaphol","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0110","article-title":"Delamanid proliposomal powder aerosols targeting alveolar macrophages for treatment of pulmonary extensively drug-resistant tuberculosis treatment: bioactivity, biocompatibility, and structure elucidation","volume":"100","author":"Tongkanarak","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.drudis.2025.104380_b0115","first-page":"336","article-title":"Carrier effect in development of rifampin loaded proliposome for pulmonary delivery: a quality by design study","volume":"12","author":"Parhizkar","year":"2022","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.drudis.2025.104380_b0120","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1093\/jac\/dkac348","article-title":"Liposomal amikacin and Mycobacterium abscessus: intimate interactions inside eukaryotic cells","volume":"77","author":"Le Moigne","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.drudis.2025.104380_b0125","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1128\/AAC.00700-16","article-title":"Pulmonary deposition and elimination of liposomal amikacin for inhalation and effect on macrophage function after administration in rats","volume":"60","author":"Malinin","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2025.104380_b0130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12951-022-01307-x","article-title":"A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases","volume":"20","author":"He","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.drudis.2025.104380_b0135","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2217\/nnm-2020-0192","article-title":"Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part II: the effect of nanoparticle charge","volume":"15","author":"Landh","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2025.104380_b0140","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s13346-018-00607-w","article-title":"Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy","volume":"9","author":"Maretti","year":"2019","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.drudis.2025.104380_b0145","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1007\/s13346-020-00849-7","article-title":"Inhalable solid lipid nanoparticles for intracellular tuberculosis infection therapy: macrophage-targeting and pH-sensitive properties","volume":"11","author":"Ma","year":"2021","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.drudis.2025.104380_b0150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijpharm.2015.11.050","article-title":"Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: physicochemical and in vitro studies","volume":"497","author":"Gaspar","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124309","article-title":"Inhalable solid lipid nanoparticles of levofloxacin for potential tuberculosis treatment","volume":"660","author":"Paul","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0160","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater Au"},{"key":"10.1016\/j.drudis.2025.104380_b0165","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2147\/IJN.S286896","article-title":"Development of inhalable nanostructured lipid carriers for ciprofloxacin for noncystic fibrosis bronchiectasis treatment","volume":"16","author":"Almurshedi","year":"2021","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.drudis.2025.104380_b0170","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijpharm.2015.12.028","article-title":"Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis","volume":"498","author":"Moreno-Sastre","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/03639045.2021.1892743","article-title":"Nanostructured lipid carrier-mediated lung targeted drug delivery system to enhance the safety and bioavailability of clofazimine","volume":"47","author":"Patil","year":"2021","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.114088","article-title":"Dual tobramycin and docosahexaenoic acid loaded nanoemulsions combating Pseudomonas aeruginosa-induced pulmonary infection","volume":"242","author":"Sun","year":"2024","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.drudis.2025.104380_b0185","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1080\/10717544.2017.1384298","article-title":"Critical physicochemical and biological attributes of nanoemulsions for pulmonary delivery of rifampicin by nebulization technique in tuberculosis treatment","volume":"24","author":"Shah","year":"2017","journal-title":"Drug Deliv"},{"key":"10.1016\/j.drudis.2025.104380_b0190","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2021.03.070","article-title":"Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure","volume":"160","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.drudis.2025.104380_b0195","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s12890-024-03261-w","article-title":"Effectiveness of amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation","volume":"24","author":"Urabe","year":"2024","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.drudis.2025.104380_b0200","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s12890-022-02257-8","article-title":"Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings","volume":"22","author":"Aksamit","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.drudis.2025.104380_b0205","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.chest.2023.05.036","article-title":"Open-label trial of amikacin liposome inhalation suspension in Mycobacterium abscessus lung disease","volume":"164","author":"Siegel","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.drudis.2025.104380_b0210","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac465","article-title":"Amikacin liposomal inhalation suspension in the treatment of Mycobacterium abscessus lung infection: a French observational experience","volume":"9","author":"Chiron","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.drudis.2025.104380_b0215","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.chest.2022.01.015","article-title":"Safety and outcomes of amikacin liposome inhalation suspension for Mycobacterium abscessus pulmonary disease: a NTM-NET study","volume":"162","author":"Henriette Zweijpfenning","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.drudis.2025.104380_b0220","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2019.08.001","article-title":"Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis","volume":"19","author":"Bilton","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.drudis.2025.104380_b0225","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jcf.2021.05.013","article-title":"Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection","volume":"20","author":"Bilton","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.drudis.2025.104380_b0230","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1513\/AnnalsATS.202008-925OC","article-title":"Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: a 12-month open-label extension clinical trial","volume":"18","author":"Winthrop","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.drudis.2025.104380_b0235","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.2147\/IDR.S427544","article-title":"Diagnosis and management of drug-induced interstitial lung disease associated with amikacin liposome inhalation suspension in refractory Mycobacterium avium complex pulmonary disease: a case report","volume":"16","author":"Hashimoto","year":"2023","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.drudis.2025.104380_b0240","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13318-020-00669-7","article-title":"Population pharmacokinetic evaluation of amikacin liposome inhalation suspension in patients with treatment-refractory nontuberculous mycobacterial lung disease","volume":"46","author":"Rubino","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.drudis.2025.104380_b0245","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.resinv.2023.12.012","article-title":"Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: a subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study","volume":"62","author":"Morimoto","year":"2024","journal-title":"Respir Investig"},{"key":"10.1016\/j.drudis.2025.104380_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/medicina60101620","article-title":"Amikacin liposomal inhalation suspension for non-tuberculous mycobacteria lung infection: a Greek observational study","volume":"60","author":"Loukeri","year":"2024","journal-title":"Medicina"},{"key":"10.1016\/j.drudis.2025.104380_b0255","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2020","article-title":"Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies","volume":"56","author":"Chalmers","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2025.104380_b0260","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jcf.2021.03.002","article-title":"Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting","volume":"20","author":"Schwarz","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.drudis.2025.104380_b0265","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jiac.2024.02.010","article-title":"Comparison of the safety and cost-effectiveness of nebulized liposomal amphotericin B and amphotericin B deoxycholate for antifungal prophylaxis after lung transplantation","volume":"30","author":"Umemura","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.drudis.2025.104380_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15122706","article-title":"Engineering inhalable therapeutic particles: conventional and emerging approaches","volume":"15","author":"Negi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2025.104380_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122739","article-title":"Colistin- and amikacin-loaded lipid-based drug delivery systems for resistant gram-negative lung and wound bacterial infections","volume":"635","author":"Vairo","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104380_b0280","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1757177419855603","article-title":"Nebuliser cleaning and disinfection practice in the home among patients with cystic fibrosis","volume":"21","author":"MacFarlane","year":"2020","journal-title":"J Infect Prev"},{"key":"10.1016\/j.drudis.2025.104380_b0285","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/jamp.2017.1400","article-title":"The development and validation of an in vitro airway model to assess realistic airway deposition and drug permeation behavior of orally inhaled products across synthetic membranes","volume":"31","author":"Huynh","year":"2018","journal-title":"J Aerosol Med Pulm Drug Deliv"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T18:01:36Z","timestamp":1749664896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625000935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1359644625000935"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104380","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in lipid-based nanoformulations for inhaled antibiotic therapy in respiratory infections","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104380"}}